Immune-Enhancing Neutrophil Reprogramming with Low-Dose Endotoxin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-cancer immunotherapies primarily focusing on adaptive immune cells have limited success, and there is a need for better characterization and reprogramming of innate neutrophils to enhance their anti-tumor function.
Innovation Solution
Reprogramming innate neutrophils with a low-dose endotoxin to induce immune-enhancing neutrophils expressing markers like CD177lo and Dectin2hi or EHD1hi, reducing immune-suppressive markers such as CD11b, and enhancing genes like CD44, CD80, and CD86.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adaptive immune cells are targeted for cancer therapy, then immune response activation is improved, but treatment effectiveness remains limited
Solution Approach 1:
The patent extends cancer immunotherapy beyond adaptive immune cells to include innate immune cells (neutrophils, monocytes, macrophages, dendritic cells), creating a multi-functional approach that combines both adaptive and innate immune mechanisms to improve treatment effectiveness and broaden therapeutic scope
2Reliability
If neutrophils are depleted to reduce tumor progression, then tumor growth inhibition is improved, but immune-enhancing potential is lost
Solution Approach 1:
The patent applies local quality by depleting only the tumor-promoting N2 neutrophil subset while preserving and expanding the immune-enhancing N1 neutrophil subset through selective targeting mechanisms, thereby achieving tumor growth inhibition without losing immune-enhancing potential
Solution Approach 2:
The patent segments the heterogeneous neutrophil population into distinct functional subsets (N1 immune-enhancing and N2 tumor-promoting) based on phenotypic markers, enabling selective manipulation of each subset to achieve opposing therapeutic effects simultaneously
3Reliability
If neutrophils are reprogrammed to enhance anti-tumor function, then immune-enhancing activity is improved, but understanding of reprogramming dynamics is insufficient
Solution Approach 1:
The patent employs feedback mechanisms by using phenotypic markers (CD177, Dectin2, EHD1, CD11b) to monitor and characterize neutrophil reprogramming status, allowing assessment of reprogramming effectiveness and identification of successful N1 phenotype conversion from N2 phenotype
Data Source
AI summary
Provided are compositions and methods for reprogramming neutrophils using low-dose endotoxin for enhancing anti-tumor immune responses. The immune-enhancing neutrophils provide therapeutic applications for neutrophil-based cancer immunotherapies. Neutrophils trained by low-dose endotoxin adopt a unique immune-enhancing cluster characterized by immune-enhancing surface markers and a reduction in immune-suppressive surface markers. The immune-enhancing neutrophils exhibit relieved suppression of adaptive T cells as compared to un-trained neutrophils and enables the generation of immune-enhancing neutrophils through activating STAT5 and reducing innate suppressor IRAK-M.